Trial Profile
A pilot phase I dose escalation study of the EGFR tyrosine kinase inhibitor gefitinib (Iressa) combined with paclitaxel (Taxol) and external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 14 Mar 2012 Actual end date changed from Oct 2010 to Nov 2010 as reported by ClinicalTrials.gov.
- 08 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.